Brokerages Expect Sophiris Bio Inc (SPHS) to Post -$0.09 Earnings Per Share
Wall Street analysts forecast that Sophiris Bio Inc (NASDAQ:SPHS) will post earnings of ($0.09) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Sophiris Bio’s earnings, with the lowest EPS estimate coming in at ($0.11) and the highest estimate coming in at ($0.08). Sophiris Bio posted earnings of ($0.13) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 30.8%. The firm is expected to announce its next quarterly earnings results on Monday, May 15th.
On average, analysts expect that Sophiris Bio will report full-year earnings of ($0.38) per share for the current fiscal year, with EPS estimates ranging from ($0.43) to ($0.33). For the next financial year, analysts forecast that the firm will post earnings of ($0.45) per share, with EPS estimates ranging from ($0.59) to ($0.33). Zacks’ EPS averages are an average based on a survey of analysts that that provide coverage for Sophiris Bio.
Sophiris Bio (NASDAQ:SPHS) last announced its quarterly earnings results on Monday, March 27th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.09.
Several equities research analysts have recently weighed in on the company. Maxim Group set a $6.00 price objective on Sophiris Bio and gave the company a “buy” rating in a research report on Saturday, March 25th. Rodman & Renshaw assumed coverage on Sophiris Bio in a research report on Monday, March 13th. They issued a “buy” rating and a $6.00 price objective for the company. Piper Jaffray Companies reissued an “overweight” rating and issued a $7.00 price objective on shares of Sophiris Bio in a research report on Thursday, April 6th. Finally, HC Wainwright assumed coverage on Sophiris Bio in a research report on Tuesday, March 14th. They issued a “buy” rating and a $6.00 price objective for the company. Six research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus target price of $6.33.
Several hedge funds and other institutional investors have recently modified their holdings of SPHS. Airain ltd raised its position in shares of Sophiris Bio by 99.1% in the third quarter. Airain ltd now owns 63,730 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 31,713 shares during the last quarter. Hudson Bay Capital Management LP purchased a new position in shares of Sophiris Bio during the third quarter worth approximately $100,000. Finally, Oxford Asset Management purchased a new position in shares of Sophiris Bio during the fourth quarter worth approximately $491,000. Institutional investors and hedge funds own 5.99% of the company’s stock.
WARNING: “Brokerages Expect Sophiris Bio Inc (SPHS) to Post -$0.09 Earnings Per Share” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at http://www.dailypolitical.com/2017/04/18/brokerages-expect-sophiris-bio-inc-sphs-to-post-0-09-earnings-per-share.html.
Shares of Sophiris Bio (NASDAQ:SPHS) traded down 1.3012% during trading on Tuesday, hitting $2.5563. 158,631 shares of the stock traded hands. Sophiris Bio has a 52 week low of $0.80 and a 52 week high of $8.55. The company’s market cap is $76.97 million. The firm’s 50-day moving average price is $2.62 and its 200-day moving average price is $2.78.
Sophiris Bio Company Profile
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sophiris Bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.